Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species

Phoenix LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 12/987,693, filed Jan 10, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 9,011,937	Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species Phoenix Biotechnology, Inc. In force Term ends Jan 10, 2031 · High confidence	Phoenix Biotechnology, Inc.	In force	Term ends Jan 10, 2031	Term ends Jan 10, 2031	High confidence
US 10,226,497	Composition for and Method of Treating Neurological Conditions Phoenix Biotechnology, Inc. In force Term ends Jan 10, 2031 · High confidence	Phoenix Biotechnology, Inc.	In force	Term ends Jan 10, 2031	Term ends Jan 10, 2031	High confidence
US 10,307,450	Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species Phoenix Biotechnology, Inc. In force Term ends Jan 10, 2031 · Medium confidence	Phoenix Biotechnology, Inc.	In force	Term ends Jan 10, 2031	Term ends Jan 10, 2031	Medium confidence
US 10,383,886	Method of Treating Neurological Conditions with Oleandrin Phoenix Biotechnology, Inc. In force Term ends Jul 2, 2031 · Medium confidence	Phoenix Biotechnology, Inc.	In force	Term ends Jul 2, 2031	Term ends Jul 2, 2031	Medium confidence
US 9,220,778	Method of Treating Neurological Conditions with Oleandrin-Containing Extract Phoenix Biotechnology, Inc. In force Term ends Feb 15, 2032 · High confidence	Phoenix Biotechnology, Inc.	In force	Term ends Feb 15, 2032	Term ends Feb 15, 2032	High confidence
US 9,358,293	Method of Treating Neurological Conditions with Oleandrin Phoenix Biotechnology, Inc. Lapsed Jun 7, 2024 on the fee record Ended Jun 7, 2024 · High confidence	Phoenix Biotechnology, Inc.	Lapsed Jun 7, 2024 on the fee record	Ended Jun 7, 2024	Ended Jun 7, 2024	High confidence
US 10,960,037	Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species Phoenix Biotechnology, Inc. Lapsed Mar 30, 2025 on the fee record Ended Mar 30, 2025 · High confidence	Phoenix Biotechnology, Inc.	Lapsed Mar 30, 2025 on the fee record	Ended Mar 30, 2025	Ended Mar 30, 2025	High confidence
US 8,481,086	Method of Treating Neurological Conditions with Cardiac Glycoside Phoenix Biotechnology, Inc. Lapsed Jul 9, 2025 on the fee record Ended Jul 9, 2025 · High confidence	Phoenix Biotechnology, Inc.	Lapsed Jul 9, 2025 on the fee record	Ended Jul 9, 2025	Ended Jul 9, 2025	High confidence
US 9,877,979	Method of Treating Neurological Conditions with Oleandrin Phoenix Biotechnology, Inc. Lapsed Jan 30, 2026 on the fee record Ended Jan 30, 2026 · High confidence	Phoenix Biotechnology, Inc.	Lapsed Jan 30, 2026 on the fee record	Ended Jan 30, 2026	Ended Jan 30, 2026	High confidence
Application 14/658,652	Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species Phoenix Biotechnology, Inc. Abandoned Abandoned Dec 27, 2017	Phoenix Biotechnology, Inc.	Abandoned	Abandoned Dec 27, 2017	not computed

10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

5 of these are in force and held by Phoenix LLC.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.